Zacks Research Issues Positive Forecast for TEVA Earnings

Key Points

• Zacks Research has increased its Q3 2027 earnings per share (EPS) estimate for Teva Pharmaceutical Industries from $0.81 to $0.83.
• Teva's recent earnings report showed an EPS of $0.66, surpassing analyst expectations of $0.64, despite revenue falling slightly short of estimates at $4.18 billion.
• Multiple research firms have upgraded their ratings and target prices for Teva, with JPMorgan and UBS raising their target price to $26.00 and assigning an "overweight" and "buy" rating respectively.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) - Research analysts at Zacks Research increased their Q3 2027 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Tuesday, October 7th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.83 per share for the quarter, up from their prior estimate of $0.81. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' FY2027 earnings at $2.84 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. During the same period in the previous year, the firm earned $0.61 EPS. The firm's revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS.

A number of other research firms also recently weighed in on TEVA. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Saturday, September 27th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an "overweight" rating in a research report on Friday, October 3rd. UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $25.57.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $20.05 on Wednesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The stock's fifty day moving average price is $18.26 and its two-hundred day moving average price is $16.87. Teva Pharmaceutical Industries has a one year low of $12.47 and a one year high of $22.80. The firm has a market cap of $23.00 billion, a price-to-earnings ratio of -125.31, a P/E/G ratio of 1.16 and a beta of 0.71.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently made changes to their positions in the company. Duquesne Family Office LLC raised its stake in shares of Teva Pharmaceutical Industries by 65.4% in the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock valued at $228,702,000 after buying an additional 5,882,350 shares during the period. Bourgeon Capital Management LLC grew its position in shares of Teva Pharmaceutical Industries by 100.7% in the second quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock valued at $12,134,000 after purchasing an additional 363,252 shares in the last quarter. Amundi grew its position in shares of Teva Pharmaceutical Industries by 18.5% in the first quarter. Amundi now owns 678,758 shares of the company's stock valued at $10,080,000 after purchasing an additional 105,846 shares in the last quarter. IFM Investors Pty Ltd grew its position in shares of Teva Pharmaceutical Industries by 9.4% in the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock valued at $3,797,000 after purchasing an additional 19,447 shares in the last quarter. Finally, Jump Financial LLC grew its position in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after purchasing an additional 838,423 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.